Acta Poloniae Pharmaceutica - Drug Research,
Год журнала:
2024,
Номер
81(1), С. 53 - 69
Опубликована: Апрель 9, 2024
Protein
kinase
CK2
has
become
a
target
of
experimental
antiglioma
therapies
as
laboratory
data
are
almost
uniformly
favorable
and
the
number
synthetized
inhibitors
is
rapidly
growing.
The
evidence
their
use
for
other
brain
tumors
on
increase
well.
Great
expectations
entrusted
in
naturally
occurring
compounds
capable
inhibiting
kinase.
These
extracted
purified
by
means
biochemistry
methods
amenable
innovative
drug
delivery
systems
have
been
proven
suitable
combined
with
investigational
agents
treatment
modalities.
However
greater
share
efforts
should
be
undertaken
towards
functions
relatively
specific
glial
including
infiltrative
growth
invasiveness
or
maintenance
glioma
initiating
cells.
Many
these
function
appear
to
converge
mTOR
JAK/STAT
pathways
which
being
meticulously
studied
this
respect.
holds
therapeutic
promise
especially
when
aimed
at
molecular
signatures
gliomas.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Янв. 29, 2024
Tripartite-motif
56
(TRIM56)
is
a
member
of
the
TRIM
family,
and
was
shown
to
be
an
interferon-inducible
E3
ubiquitin
ligase
that
can
overexpressed
upon
stimulation
with
double-stranded
DNA
regulate
stimulator
interferon
genes
(STING)
produce
type
I
thus
mediate
innate
immune
responses.
Its
role
in
tumors
remains
unclear.
In
this
study,
we
investigated
relationship
between
expression
TRIM56
gene
its
prognostic
value
pan-cancer,
identifying
as
adverse
factor
glioma
patients.
Therefore,
selected
primary
focus
our
investigation.
We
explored
differential
various
subtypes
verified
independent
gliomas.
Our
research
revealed
associated
malignant
biological
behaviors
gliomas,
such
proliferation,
migration,
invasion.
Additionally,
it
M2
polarization
macrophages
The
results
were
validated
vitro
vivo.
Furthermore,
utilized
single-cell
analysis
investigate
impact
on
cell
communication
cells
non-tumor
cells.
constructed
multi-gene
signature
based
markers
tumor
high
enhance
prediction
cancer
patient
prognosis.
conclusion,
study
demonstrates
serves
reliable
immune-related
biomarker
glioma.
Heliyon,
Год журнала:
2024,
Номер
10(11), С. e31875 - e31875
Опубликована: Май 25, 2024
BackgroundNumerous
studies
have
shown
a
strong
correlation
between
disulfidptosis
and
various
cancers.
However,
the
expression
function
of
RPN1,
crucial
gene
in
disulfidptosis,
remain
unclear
context
cancer.MethodsGene
clinical
information
on
lung
adenocarcinoma
were
obtained
from
The
Cancer
Genome
Atlas
(TCGA)
Genotype-Tissue
Expression
(GTEx)
databases.
RPN1
was
analyzed
using
Timer2.0
Human
Protein
(HPA)
Prognostic
significance
assessed
Cox
regression
analysis
Kaplan–Meier
curves.
Genetic
mutations
methylation
levels
examined
cBioPortal
UALCAN
platforms,
respectively.
relationship
tumor
mutation
burden
(TMB)
microsatellite
instability
(MSI)
across
different
cancer
types
Spearman
coefficient.
immune
cell
infiltration
database,
whereas
variations
drug
sensitivity
explored
CellMiner
database.
Receiver
operating
characteristic
curves
validated
RPN1's
diagnostic
potential
glioma,
its
with
checkpoint
inhibitors
(ICIs)
Spearman's
Single-sample
set
enrichment
elucidated
link
cells
pathways.
In
addition,
nomogram
based
developed
to
predict
patient
prognosis.
functional
impact
glioma
confirmed
scratch
Transwell
assays.ResultRPN1
aberrantly
expressed
cancers
affected
main
type
amplified.
exhibited
positive
myeloid-derived
suppressor
cells,
neutrophils,
macrophages,
negative
CD8+
T
hematopoietic
stem
cells.
associated
TMB
MSI
positively
correlated
multiple
ICIs
gliomas.
also
into
microenvironment.
an
independent
prognostic
factor
for
gliomas,
demonstrated
excellent
predictive
performance.
Interference
reduces
migratory
invasive
ability
cells.ConclusionRPN1
exerts
multifaceted
effects
stages
cancer,
including
infiltration,
prognosis,
treatment
outcomes.
affects
prognosis
microenvironment
patients
making
target
glioma.
Abstract
Glioblastoma
(GBM)
is
the
most
common
malignant
brain
tumor,
which,
despite
significant
progress
made
in
last
years
field
of
neuro-oncology,
remains
an
incurable
disease.
GBM
has
a
poor
prognosis
with
median
survival
12–15
months,
and
its
aggressive
clinical
course
related
to
rapid
growth,
extensive
infiltration
adjacent
tissues,
resistance
chemotherapy,
radiotherapy
immunotherapy,
frequent
relapse.
Currently,
several
molecular
biomarkers
are
used
practice
predict
patient
response
treatment.
However,
due
overall
unsatisfactory
efficacy
standard
multimodal
treatment
remaining
prognosis,
there
urgent
need
for
new
therapeutic
strategies
GBM.
Recent
evidence
suggests
that
tumorigenesis
associated
crosstalk
between
cancer,
immune
stromal
cells
mediated
by
various
cytokines.
One
key
factors
involved
this
process
appears
be
interleukin-17
(IL-17),
pro-inflammatory
cytokine
significantly
upregulated
serum
tissue
patients.
IL-17
plays
role
tumorigenesis,
angiogenesis,
recurrence
activating
pro-oncogenic
signaling
pathways
promoting
cell
survival,
proliferation,
invasion.
facilitates
immunomodulation
tumor
microenvironment
secretion.
In
article
we
review
latest
scientific
reports
provide
update
on
microenvironment,
diagnosis,
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics,
Год журнала:
2024,
Номер
32(8), С. 1239 - 1256
Опубликована: Янв. 1, 2024
Glioblastoma
multiforme
(GBM)
is
an
aggressive
primary
brain
tumor
characterized
by
extensive
heterogeneity
and
vascular
proliferation.
Hypoxic
conditions
in
the
tissue
microenvironment
are
considered
a
pivotal
player
leading
progression.
Specifically,
hypoxia
known
to
activate
inducible
factors,
such
as
hypoxia-inducible
factor
1alpha
(HIF-1α),
which
turn
can
stimulate
neo-angiogenesis
through
activation
of
various
downward
mediators,
endothelial
growth
(VEGF).
Here,
we
aimed
explore
role
HIF-1α/VEGF
immunophenotypes
alone
combination
with
other
prognostic
markers
or
clinical
image
analysis
data,
potential
biomarkers
GBM
prognosis
treatment
efficacy.
We
performed
systematic
review
(Medline/Embase,
Pubmed
database
search
was
completed
16th
April
2024
two
independent
teams;
PRISMA
2020).
evaluated
methods
immunoassays,
cell
viability,
animal
patient
survival
retrieved
studies
assess
unbiased
data.
used
inclusion
criteria,
evaluation
based
on
expression,
imaging
manifestations
related
application
immunoassays
for
protein
effectiveness
therapeutic
strategies
expression.
exclusion
data
not
reporting
both
HIF-1α
VEGF
prognosis.
included
50
investigating
total
1319
human
specimens,
18
different
lines
GBM-derived
stem
cells,
6
models,
identify
association
immunophenotypes,
macroscopic
approaches.
found
that
increased
expression
correlates
oncogenic
miR-210-3p,
Oct4,
AKT,
COX-2,
PDGF-C,
PLDO3,
M2
polarization,
ALK,
unfavorable
survival.
Reduced
FIH-1,
ADNP,
STAT1
upregulation,
well
manifestations,
like
epileptogenicity,
favorable
GBM.
Based
our
may
be
useful
tool
clarify
MRI-PET
distinguishing
between
progression
pseudoprogression.
Finally,
reflect
efficacy,
including
combined
first-line
histone
deacetylase
inhibitors,
thimerosal,
active
metabolite
irinotecan,
STAT3
inhibitors
alone,
resulting
These
were
supported
variable
evaluate
immunophenotypes.
Data
limitations
include
use
less
sensitive
detection
some
cases.
Overall,
support
HIF-1α/VEGF's
Journal of Advanced Research,
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 1, 2024
With
the
gradual
understanding
of
glioma
development
and
immune
microenvironment,
many
cells
have
been
discovered.
Despite
growing
comprehension
cell
functions
clinical
application
immunotherapy,
precise
roles
characteristics
subtypes,
how
induces
subtype
transformation
its
impact
on
progression
yet
to
be
understood.
In
this
review,
we
comprehensively
center
four
major
within
particularly
neutrophils,
macrophages,
lymphocytes,
myeloid-derived
suppressor
(MDSCs),
other
significant
cells.
We
discuss
(1)
markers,
(2)
glioma-induced
transformation,
(3)
mechanisms
each
influencing
chemotherapy
resistance,
(4)
therapies
targeting
cells,
(5)
cell-associated
single-cell
sequencing.
Eventually,
identified
subtypes
in
glioma,
summarized
exact
mechanism
concluded
progress
sequencing
exploring
glioma.
conclusion,
analyzed
resistance
detailly,
discovered
prospective
immunotherapy
targets,
excavating
potential
novel
immunotherapies
approach
that
synergistically
combines
radiotherapy,
chemotherapy,
surgery,
thereby
paving
way
for
improved
immunotherapeutic
strategies
against
enhanced
patient
outcomes.
Carcinogenesis,
Год журнала:
2023,
Номер
45(4), С. 235 - 246
Опубликована: Дек. 23, 2023
Abstract
Glioma
is
the
most
common
malignant
brain
tumor
in
adults
with
a
high
mortality
and
recurrence
rate.
Integrin
alpha
2
(ITGA2)
involved
cell
adhesion,
stem
regulation,
angiogenesis
immune
function.
The
role
of
ITGA2
glioma
invasion
remains
unknown.
function
clinical
relevance
were
analysed
by
bioinformatics
databases.
expression
parent
cells
GSCs
was
detected
flow
cytometry
immunofluorescence
double
staining.
on
phenotype
epithelial–mesenchymal
transition
(EMT)
identified
assays
Western
blot.
effect
progression
vivo
determined
intracranial
orthotopic
xenograft
model.
Immunohistochemistry,
Spearman
correlation
Kaplan–Meier
used
to
analyse
relationship
features
prognosis.
Biological
analysis
showed
that
might
be
related
migration.
ITGA2,
enriched
co-expressed
SOX2,
promoted
migration
activating
STAT3
phosphorylation
enhancing
EMT.
knockout
suppressed
growth
prolonged
survival
mice.
In
addition,
level
significantly
correlated
grade
malignancy,
N-cadherin
Ki67.
High
indicated
worse
prognosis
patients.
As
biomarker
for
prediction
prognosis,
promotes
EMT,
leading
poor
Biology,
Год журнала:
2023,
Номер
12(10), С. 1295 - 1295
Опубликована: Сен. 28, 2023
Despite
countless
papers
in
the
field
of
radioresistance,
researchers
are
still
far
from
clearly
understanding
mechanisms
triggered
glioblastoma.
Cancer
stem
cells
(CSC)
important
to
growth
and
spread
cancer,
according
many
studies.
In
addition,
more
recently,
it
has
been
suggested
that
CSCs
have
an
impact
on
glioblastoma
patients’
prognosis,
tumor
aggressiveness,
treatment
outcomes.
reviewing
this
new
area
biology,
we
will
provide
a
summary
most
recent
research
their
role
response
radio-chemotherapy
GB.
review,
examine
radiosensitivity
cells.
Moreover,
summarize
current
knowledge
biomarkers
stemness
evaluate
potential
function
study
radiosensitivity.
Glioblastoma
is
a
malignant
and
aggressive
type
of
central
nevous
system
malignancy
characterized
by
many
distinct
biological
features
including
extensive
hypoxia.
Hypoxia
in
glioblatoma
associates
with
complex
signaling
patterns
activation
several
pathways
such
as
MAPK,
PI3K-AKT/mTOR
IL-6/JAK/STAT3
the
master
regulator
HIF-1,
which
turn
drive
particular
tumor
behaviors
determining,
end,
treatment
outcomes
patients
fate.
Thus,
present
study
was
designed
to
investigate
expression
selected
hypoxia
related
factors
STAT3
small
set
long-term
surviving
glioma
patients.
